Unnamed: 0,title,date,stock,sentiment
312654.0,Catalent Announces $550M Common Stock Offering,2020-06-10 16:07:00-04:00,CTLT,neutral
312655.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,CTLT,positive
312656.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-26 10:32:00-04:00,CTLT,neutral
312657.0,"The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive",2020-05-21 08:01:00-04:00,CTLT,neutral
312658.0,"Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.",2020-05-20 11:19:00-04:00,CTLT,positive
312659.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-20 10:38:00-04:00,CTLT,neutral
312660.0,"In The Midst Of Pandemic, Traders Pin Their Hopes On These Healthcare ETFs",2020-05-19 09:38:00-04:00,CTLT,positive
312661.0,Stocks That Hit 52-Week Highs On Monday,2020-05-18 10:44:00-04:00,CTLT,neutral
312662.0,Shares of several healthcare companies are trading higher in sympathy with the overall market as optimism around a coronavirus vaccine increased following news from Moderna.,2020-05-18 10:23:00-04:00,CTLT,positive
312663.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,CTLT,positive
312664.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-13 10:35:00-04:00,CTLT,neutral
312665.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,CTLT,neutral
312666.0,Stocks That Hit 52-Week Highs On Thursday,2020-05-07 10:33:00-04:00,CTLT,neutral
312667.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,CTLT,negative
312668.0,Catalent shares are trading higher after several firms maintained their bullish ratings and raised their price targets on the company's stock after the company reported its Q3 earnings results yesterday.,2020-05-06 13:35:00-04:00,CTLT,positive
312669.0,"Baird Maintains Outperform on Catalent, Raises Price Target of $74",2020-05-06 11:33:00-04:00,CTLT,neutral
312670.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-06 10:43:00-04:00,CTLT,neutral
312671.0,"UBS Maintains Buy on Catalent, Raises Price Target to $77",2020-05-06 09:07:00-04:00,CTLT,neutral
312672.0,"Morgan Stanley Maintains Overweight on Catalent, Raises Price Target to $75",2020-05-06 08:33:00-04:00,CTLT,negative
312673.0,"Deutsche Bank Maintains Hold on Catalent, Raises Price Target to $62",2020-05-06 07:55:00-04:00,CTLT,neutral
312674.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,CTLT,positive
312675.0,"Catalent Q3 EPS $0.500 Beats $0.480 Estimate, Sales $760.600M Beat $692.540M Estimate",2020-05-05 07:44:00-04:00,CTLT,neutral
312676.0,Arcturus Reports Partnership With Catalent To Manufacture mRNA-Based Coronavirus Vaccine,2020-05-04 08:40:00-04:00,CTLT,neutral
312677.0,Shares of several healthcare companies are trading lower as markets dip following recent strength. Markets have sold off as investors weigh recent earnings and amid concerns of renewed US-China trade frictions.,2020-05-01 12:35:00-04:00,CTLT,positive
312678.0,"The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO",2020-05-01 07:54:00-04:00,CTLT,neutral
312679.0,Stocks That Hit 52-Week Highs On Wednesday,2020-04-29 10:16:00-04:00,CTLT,neutral
312680.0,Catalent Signs Agreement With Johnson & Johnson To Be US Manufacturing Partner For Lead Coronavirus Vaccine Candidate,2020-04-29 08:04:00-04:00,CTLT,positive
312681.0,"Benzinga's Top Upgrades, Downgrades For April 21, 2020",2020-04-21 09:35:00-04:00,CTLT,positive
312682.0,"RBC Capital Initiates Coverage On Catalent with Outperform Rating, Announces Price Target to $65",2020-04-21 06:52:00-04:00,CTLT,neutral
312683.0,"Baird Maintains Outperform on Catalent, Lowers Price Target to $63",2020-04-13 10:50:00-04:00,CTLT,negative
312684.0,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,2020-04-01 09:20:00-04:00,CTLT,negative
312685.0,"Morgan Stanley Maintains Overweight on Catalent, Lowers Price Target to $57",2020-03-27 09:19:00-04:00,CTLT,negative
312686.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,CTLT,positive
312687.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,CTLT,negative
312688.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,CTLT,positive
312689.0,"Benzinga's Top Upgrades, Downgrades For March 2, 2020",2020-03-02 09:40:00-05:00,CTLT,positive
312690.0,"Deutsche Bank Initiates Coverage On Catalent with Hold Rating, Announces $59 Price Target",2020-03-02 07:37:00-05:00,CTLT,neutral
312691.0,"A Peek Into The Markets: US Stock Futures Up Ahead Of Home-Price, Consumer Confidence Data",2020-02-25 06:13:00-05:00,CTLT,positive
312692.0,"Perrigo, Catalent Announce FDA Approval of Perrigo's AB-rated Generic Version of ProAir HFA",2020-02-25 05:26:00-05:00,CTLT,positive
312693.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,CTLT,negative
312694.0,"Baird Maintains Outperform on Catalent, Raises Price Target to $67",2020-02-04 08:47:00-05:00,CTLT,neutral
312695.0,"Morgan Stanley Maintains Overweight on Catalent, Raises Price Target to $67",2020-02-04 08:07:00-05:00,CTLT,negative
312696.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,CTLT,negative
312697.0,11 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-02-04 07:43:00-05:00,CTLT,neutral
312698.0,3 Drug Manufacturersâ€”Specialty & Generic Stocks Moving In Tuesday's Pre-Market Session,2020-02-04 07:41:00-05:00,CTLT,neutral
312699.0,33 Stocks Moving in Tuesday's Pre-Market Session,2020-02-04 07:24:00-05:00,CTLT,neutral
312700.0,Catalent Prices Public Offering of Common Stock for Gross Proceeds of $500M,2020-02-03 18:50:00-05:00,CTLT,negative
312701.0,Catalent Announces $500M Common Stock Offering,2020-02-03 16:12:00-05:00,CTLT,neutral
312702.0,Stocks That Hit 52-Week Highs On Monday,2020-02-03 11:44:00-05:00,CTLT,neutral
312703.0,Catalent To Buy Cell Therapy CDMO MasTherCell For $315M,2020-02-03 10:32:00-05:00,CTLT,neutral
312704.0,Catalent Revises FY20 Sales Guidance From $2.78B-$2.88B To $2.87B-$2.95B vs $2.85B Est.,2020-02-03 07:34:00-05:00,CTLT,neutral
312705.0,"Catalent Q2 Adj. EPS $0.45 Beats $0.44 Estimate, Sales $721.4M Beat $699.51M Estimate",2020-02-03 07:33:00-05:00,CTLT,neutral
312706.0,Catalent To Acquire Cell Therapy Company MaSTherCell Global For $315M,2020-02-03 07:29:00-05:00,CTLT,neutral
312707.0,"Earnings Scheduled For February 3, 2020",2020-02-03 04:28:00-05:00,CTLT,neutral
312708.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,CTLT,neutral
312709.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,CTLT,positive
312710.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-29 10:16:00-05:00,CTLT,neutral
312711.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,CTLT,neutral
312712.0,Stocks That Hit 52-Week Highs On Monday,2020-01-27 10:33:00-05:00,CTLT,neutral
312713.0,"Stephens & Co. Maintains Overweight on Catalent, Raises Price Target to $75",2020-01-27 07:25:00-05:00,CTLT,negative
312714.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,CTLT,neutral
312715.0,Catalent Furthers Stregthenes Its Biologics Business With Key Senior Appointments,2020-01-16 16:16:00-05:00,CTLT,neutral
312716.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,CTLT,neutral
312717.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-15 13:14:00-05:00,CTLT,neutral
312718.0,"Catalent Q1 EPS $(0.05) May Not Compare To $0.24 Estimate, Sales $664.7M Beat $636.72M Estimate",2019-11-05 07:31:00-05:00,CTLT,neutral
312719.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,CTLT,negative
312720.0,"Stephens & Co. Reinstates Overweight on Catalent, Announces $56 Price Target",2019-10-17 07:43:00-04:00,CTLT,negative
312721.0,Catalent And Minerva Neurosciences Enter Commercial Supply Agreement For Schizophrenia Drug Roluperidone,2019-09-24 09:04:00-04:00,CTLT,positive
312722.0,Catalent Analyst Cites Valuation Concerns In Downgrade,2019-08-28 14:42:00-04:00,CTLT,neutral
312723.0,10 Biggest Price Target Changes For Wednesday,2019-08-28 09:02:00-04:00,CTLT,neutral
312724.0,"Baird Maintains Outperform on Catalent, Raises Price Target to $60",2019-08-28 08:39:00-04:00,CTLT,neutral
312725.0,"Morgan Stanley Maintains Overweight on Catalent, Raises Price Target to $61",2019-08-28 08:03:00-04:00,CTLT,negative
312726.0,"UPDATE: KeyBanc Downgrades Catalent To Sector Weight As Firm Notes 'We are downgrading CTLT on valuation, with the shares now at near all-time highs (~15x CY20 EBITDA)'",2019-08-28 06:53:00-04:00,CTLT,positive
312727.0,KeyBanc Downgrades Catalent to Sector Weight,2019-08-28 06:07:00-04:00,CTLT,neutral
312728.0,Catalent Reports Q4 Earnings Beat,2019-08-27 07:48:00-04:00,CTLT,neutral
312729.0,Catalent Sees FY20 Sales $2.78B-$2.88B vs $2.84B Est.,2019-08-27 07:37:00-04:00,CTLT,neutral
312730.0,"Catalent Q4 EPS $0.7 Beats $0.64 Estimate, Sales $725.7M Beat $721.03M Estimate",2019-08-27 07:36:00-04:00,CTLT,neutral
312731.0,"Earnings Scheduled For August 27, 2019",2019-08-27 04:12:00-04:00,CTLT,neutral
312732.0,Catalent's Q4 Earnings Outlook,2019-08-26 14:35:00-04:00,CTLT,neutral
312733.0,New Equities that Broke Through 52-Week Highs Monday Morning,2019-07-29 10:13:00-04:00,CTLT,negative
312734.0,Companies That Achieved 52-Week Highs Friday,2019-07-26 15:37:00-04:00,CTLT,neutral
312735.0,Catalent Reports Agreement With  Sanofi Active Ingredient Solutions Under Which Co. Will Have Access To Spray Drying Manufacturing Services,2019-07-09 07:04:00-04:00,CTLT,positive
312736.0,Novavax Takes Accelerated Approval Pathway For Flu Vaccine Development,2019-06-27 10:51:00-04:00,CTLT,positive
312737.0,68 Biggest Movers From Friday,2019-06-24 04:25:00-04:00,CTLT,neutral
312738.0,44 Stocks Moving In Friday's Mid-Day Session,2019-06-21 12:13:00-04:00,CTLT,neutral
312739.0,Catalent shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised the price target from $50 to $62.,2019-06-21 10:13:00-04:00,CTLT,positive
312740.0,10 Biggest Price Target Changes For Friday,2019-06-21 09:50:00-04:00,CTLT,neutral
312741.0,"Benzinga's Top Upgrades, Downgrades For June 21, 2019",2019-06-21 09:15:00-04:00,CTLT,positive
312742.0,"Jefferies Upgrades Catalent to Buy, Raises Price Target to $62",2019-06-21 06:52:00-04:00,CTLT,neutral
312743.0,Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Italy,2019-06-19 13:25:00-04:00,CTLT,neutral
312744.0,"Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy, No Terms Disclosed",2019-06-19 06:59:00-04:00,CTLT,negative
312745.0,Catalent Narrows FY2019 Sales Guidance from $2.5B-2.59B to $2.5B-2.52B,2019-05-07 07:54:00-04:00,CTLT,neutral
312746.0,"Catalent Q3 EPS $0.49 Beats $0.46 Estimate, Sales $617.5M Miss $644.98M Estimate",2019-05-07 07:53:00-04:00,CTLT,negative
312747.0,"Benzinga's Top Upgrades, Downgrades For April 16, 2019",2019-04-16 08:54:00-04:00,CTLT,positive
312748.0,"UBS Upgrades Catalent to Buy, Raises Price Target to $54",2019-04-16 07:34:00-04:00,CTLT,neutral
312749.0,44 Biggest Movers From Yesterday,2019-04-16 05:44:00-04:00,CTLT,neutral
312750.0,34 Stocks Moving In Monday's Mid-Day Session,2019-04-15 12:16:00-04:00,CTLT,neutral
312751.0,Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Posts Mixed Q1 Results,2019-04-15 10:24:00-04:00,CTLT,negative
312752.0,Catalent shares are trading higher after the company announced it would acquire Paragon Services for $1.2 billion.,2019-04-15 09:37:00-04:00,CTLT,positive
312753.0,Catalent Agrees To Buy Gene Therapy-Focused CDMO Paragon Services For $1.2B,2019-04-15 09:27:00-04:00,CTLT,positive
312754.0,Catalent to Acquire Paragon Bioservices for $1.2B,2019-04-15 07:01:00-04:00,CTLT,neutral
312755.0,Catalent to Acquire Paragon Bioservices for $1.2B in Cash,2019-04-14 19:49:00-04:00,CTLT,neutral
312756.0,Catalent Announces the First Patient Has Been Dosed in its Phase 1 Clinical Trial of its B-Cell Lymphona Treatment,2019-04-01 08:44:00-04:00,CTLT,neutral
312757.0,Catalent Option Alert: Apr 18 $40 Calls at the Ask: 500 @ $1.65 vs 1395 OI; Earnings 4/30 Before Open [est] Ref=$40.63,2019-03-26 13:45:00-04:00,CTLT,positive
312758.0,Catalent Option Alert: Apr 18 $45 Calls at the Ask: 500 @ $0.5 vs 3199 OI; Earnings 4/30 Before Open [est] Ref=$42.0,2019-03-12 15:15:00-04:00,CTLT,positive
312759.0,Catalent Names Alessandro Maselli President And COO,2019-02-13 07:14:00-05:00,CTLT,neutral
312760.0,50 Biggest Movers From Yesterday,2019-02-06 05:03:00-05:00,CTLT,neutral
312761.0,"Catalent shares are trading higher after the company reported Q2 EPS Q2 of $0.45, beating the $0.37 estimate and sales of $623 million, beating the $607.91M estimate.",2019-02-05 12:53:00-05:00,CTLT,negative
312762.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-02-05 12:35:00-05:00,CTLT,neutral
312763.0,"Catalent Reaffirms FY19 Sales $2.5B-$2.59B, Adj. EBITDA $597M-$622M, Adj. Net Income $260M-$285M",2019-02-05 07:34:00-05:00,CTLT,neutral
312764.0,"Catalent Q2 EPS $0.45 Beats $0.37 Estimate, Sales $623M Beat $607.91M Estimate",2019-02-05 07:34:00-05:00,CTLT,neutral
312765.0,"Earnings Scheduled For February 5, 2019",2019-02-05 04:01:00-05:00,CTLT,neutral
312766.0,Catalent Announces $200M Capital Investment in Biologics,2019-01-07 07:07:00-05:00,CTLT,neutral
312767.0,Catalent Shares Fall ~1.3% Over Last Few Mins As Traders Circulate Word France's ANSM Posted An Injunction Letter To Co.'s French Subsidiary Highlighting Various Non-Compliant Issues Have Still Not Been Resolved,2018-12-27 10:16:00-05:00,CTLT,positive
312768.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,CTLT,negative
312769.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,CTLT,negative
312770.0,"Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018",2018-12-17 11:48:00-05:00,CTLT,negative
312771.0,Biohaven Announces Positive Phase 3 Results with Rimegepant Zydis Orally Dissolving Tablet for the Acute Treatment of Migraine,2018-12-03 03:59:00-05:00,CTLT,positive
312772.0,"Baird Initiates Coverage On Catalent, Cambrex With Outperform Ratings",2018-11-15 16:59:00-05:00,CTLT,neutral
312773.0,"First Analysis Upgrades Catalent to Outperform, Lowers Price Target to $43",2018-11-07 11:12:00-05:00,CTLT,negative
312774.0,75 Biggest Movers From Yesterday,2018-11-07 04:00:00-05:00,CTLT,neutral
312775.0,60 Stocks Moving In Tuesday's Mid-Day Session,2018-11-06 12:36:00-05:00,CTLT,neutral
312776.0,"Catalent Reaffirms FY19 Guidance: Sales $2.5B-$2.59B vs $2.56B Estimate, Adj. EBITDA $597M-$622M, Adj. Net Income $260M-$285M",2018-11-06 07:32:00-05:00,CTLT,neutral
312777.0,"Catalent Q1 EPS $0.28, Inline, Sales $551.8M Miss $582.44M Estimate",2018-11-06 07:31:00-05:00,CTLT,negative
312778.0,"World Health Organization's Emergency Committee Has Said The Ebola Outbreak In Congo Is Not Yet A Health Emergency Of Int'l. Concern, Warns Situation Likely To Deteriorate Significantly Unless Response Is Intensified",2018-10-17 13:27:00-04:00,CTLT,negative
312779.0,Democratic Republic Of Congo Confirms Ebola Case In Ituri Province Almost 200 KM Away From Closest Other Case And 50 KM From The Ugandan Border,2018-09-21 10:03:00-04:00,CTLT,neutral
312780.0,"Catalent Director Morel Buys 10,000 @ Avg Price: $43.00",2018-09-17 11:02:00-04:00,CTLT,neutral
312781.0,"Ebola-Related Stocks Unaffected Amid Earlier Report Officials In Congo Announced The First Ebola Case In A Major Eastern City, Butembo",2018-09-05 07:56:00-04:00,CTLT,neutral
312782.0,Catalent Sees FY19 Sales $2.50B-$2.59B vs $2.62B Est.,2018-08-28 07:31:00-04:00,CTLT,neutral
312783.0,"Catalent Q4 Adj. EPS $0.67 Beats $0.61 Estimate, Sales $685.3M Miss $689.49M Estimate",2018-08-28 07:30:00-04:00,CTLT,negative
312784.0,"Earnings Scheduled For August 28, 2018",2018-08-28 04:07:00-04:00,CTLT,neutral
312785.0,Democratic Republic of Congo Health Ministry Says Starts Using Experimental Ebola Treatment MAB114 vs Outbreak in Eastern Provinces,2018-08-14 04:50:00-04:00,CTLT,neutral
312786.0,Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals for $11.50/Share,2018-08-14 04:04:00-04:00,CTLT,positive
312787.0,Catalent Late Tuesday Priced ~9.94M Share Common Stock Offering At $40.24/Share,2018-07-25 09:20:00-04:00,CTLT,positive
312788.0,Catalent 8-K Shows Co. Sees Q4 Sales $683M-$686M vs $690M Estimate,2018-07-23 16:57:00-04:00,CTLT,neutral
312789.0,Catalent Reports Offering Of $400M Common Stock Offering,2018-07-23 16:12:00-04:00,CTLT,neutral
312790.0,45 Biggest Movers From Tuesday,2018-07-05 04:40:00-04:00,CTLT,neutral
312791.0,34 Stocks Moving In Tuesday's Mid-Day Session,2018-07-03 12:30:00-04:00,CTLT,neutral
312792.0,Mid-Day Market Update: U.S. Stocks Turn Negative; Anavex Life Sciences Shares Spike Higher,2018-07-03 12:15:00-04:00,CTLT,negative
312793.0,Mid-Morning Market Update: Markets Open Higher; Acuity Brands Beats Q3 Expectations,2018-07-03 10:14:00-04:00,CTLT,neutral
312794.0,20 Stocks Moving In Tuesday's Pre-Market Session,2018-07-03 08:04:00-04:00,CTLT,neutral
312795.0,"Benzinga's Daily Biotech Pulse: Titan's Parkinson's Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% Premium",2018-07-03 07:51:00-04:00,CTLT,neutral
312796.0,Juniper Pharmaceuticals Signs Definitive Agreement to be Acquired by Catalent for $11.50/Share in Cash,2018-07-03 04:01:00-04:00,CTLT,positive
312797.0,"William Blair Growth Stock Conference Begins Today, Presenters Include: Aspen Technology, Ellie Mae, FleetCor, Catalent, SendGrid, DexCom, Discover Financial, and Okta",2018-06-12 07:16:00-04:00,CTLT,positive
312798.0,"Catalent Reaffirms FY18 Outlook: Sales $2.42B-$2.48B vs $2.45B Est., Adj. EBITDA $537M-$557M, Adj. Net Income $212M-$232M",2018-05-01 07:46:00-04:00,CTLT,neutral
312799.0,"Catalent Q3 Adj. EPS $0.41 Beats $0.39 Est., Sales $627.9M Beats $609M Est.",2018-05-01 07:46:00-04:00,CTLT,neutral
312800.0,Catalent Q3 Earnings Outlook,2018-04-30 14:48:00-04:00,CTLT,neutral
312801.0,'Uniquely Positioned' Catalent Notches KeyBanc Upgrade,2018-03-28 10:06:00-04:00,CTLT,neutral
312802.0,"Benzinga's Top Upgrades, Downgrades For March 28, 2018",2018-03-28 09:31:00-04:00,CTLT,positive
312803.0,"The Market In 5 Minutes: Longfin, Apple, Tesla, Shire And More",2018-03-28 09:16:00-04:00,CTLT,neutral
312804.0,KeyBanc Upgrades Catalent to Overweight,2018-03-28 06:22:00-04:00,CTLT,negative
312805.0,Raymond James Projects 'Rising Momentum' At Catalent Driven By Biologics Expansion,2018-03-21 14:57:00-04:00,CTLT,neutral
312806.0,"Benzinga's Top Upgrades, Downgrades For March 21, 2018",2018-03-21 09:31:00-04:00,CTLT,positive
312807.0,Raymond James Upgrades Catalent to Outperform,2018-03-21 07:12:00-04:00,CTLT,neutral
312808.0,Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis Orally Dissolving Tablet,2018-03-01 03:54:00-05:00,CTLT,positive
312809.0,"RBC Capital Global Healthcare Conference Concludes Today, Presenters Include: Catalent, Spectrum Pharma, and Akebia Therapeutics",2018-02-22 06:58:00-05:00,CTLT,neutral
312810.0,Biohaven Enters Exclusive License Agreement With Catalent for Zydis ODT With Small Molecule Cgrp Receptor Antagonists,2018-02-21 03:54:00-05:00,CTLT,positive
312811.0,"13F From Cooperman's Omega Shows Liquidated Positions In Cotiviti, Catalent, Covanta",2018-02-14 12:18:00-05:00,CTLT,neutral
312812.0,"Benzinga's Top Upgrades, Downgrades For February 6, 2018",2018-02-06 09:52:00-05:00,CTLT,positive
312813.0,"The Market In 5 Minutes: Markets Plummet, Volatility Spikes",2018-02-06 09:00:00-05:00,CTLT,neutral
312814.0,Stephens & Co. Downgrades Catalent to Equal-Weight,2018-02-06 07:49:00-05:00,CTLT,neutral
312815.0,"Earnings Scheduled For February 5, 2018",2018-02-05 04:28:00-05:00,CTLT,neutral
312816.0,"ICYMI: MicroCap Trading Ideas, Puma Biotech, A Valeant Bear Call",2018-01-24 17:20:00-05:00,CTLT,neutral
312817.0,"Goldman Sachs On Specialty Pharma: Buy Catalent, Sell Valeant",2018-01-24 11:27:00-05:00,CTLT,neutral
312818.0,"Goldman Sachs Initiates Coverage On Catalent with Buy Rating, Announces $50.00 Price Target",2018-01-24 08:26:00-05:00,CTLT,neutral
312819.0,"Benzinga's Top Upgrades, Downgrades For January 8, 2018",2018-01-08 09:38:00-05:00,CTLT,positive
312820.0,First Analysis Initiates Coverage On Catalent with Equal-Weight Rating,2018-01-08 08:25:00-05:00,CTLT,neutral
312821.0,"Benzinga's Top Upgrades, Downgrades For December 13, 2017",2017-12-13 09:01:00-05:00,CTLT,positive
312822.0,"RBC Capital Initiates Coverage On Catalent with Outperform Rating, Announces $46.00 Price Target",2017-12-13 06:44:00-05:00,CTLT,neutral
312823.0,"Catalent Sees FY18 Sales $2.31B-$2.41B vs $2.31B Est., Adj. EBITDA $521M-$547M, Adj. Net Income $198M-$224M",2017-11-06 07:33:00-05:00,CTLT,neutral
312824.0,"Catalent Reports Q1 Adj. EPS $0.21 vs $0.18 Est., Adj. EBITDA $90.9M, Sales $543.9M vs $491M Est.",2017-11-06 07:32:00-05:00,CTLT,neutral
312825.0,"Companies Holding Annual Shareholder Meetings Today Include: Lumentum, Mesa Laboratories, SINA, Weibo, Western Digital, Zayo Group, and Catalent",2017-11-02 09:13:00-04:00,CTLT,neutral
312826.0,Catalent Prices 6.395M Share Offering @$39.10/Share,2017-09-27 04:41:00-04:00,CTLT,positive
312827.0,Catalent Announces Offering $250M Common Stock,2017-09-25 16:12:00-04:00,CTLT,neutral
312828.0,The Market In 5 Minutes,2017-09-21 09:55:00-04:00,CTLT,neutral
312829.0,"Benzinga's Top Upgrades, Downgrades For September 21, 2017",2017-09-21 09:14:00-04:00,CTLT,positive
312830.0,Morgan Stanley Upgrades Catalent to Overweight,2017-09-21 06:12:00-04:00,CTLT,negative
312831.0,Catalent Reports Purchase Of Cook Pharmica For $950M,2017-09-19 07:30:00-04:00,CTLT,neutral
312832.0,"Benzinga's Top Upgrades, Downgrades For September 13, 2017",2017-09-13 09:21:00-04:00,CTLT,positive
312833.0,"Needham Initiates Coverage On Catalent with Hold Rating, Announces $42.00 Price Target",2017-09-13 07:37:00-04:00,CTLT,neutral
312834.0,"Benzinga's Top Upgrades, Downgrades For September 8, 2017",2017-09-08 09:20:00-04:00,CTLT,positive
312835.0,The Market In 5 Minutes,2017-09-08 08:44:00-04:00,CTLT,neutral
312836.0,KeyBanc Downgrades Catalent to Sector Weight,2017-09-08 06:22:00-04:00,CTLT,neutral
312837.0,Mid-Afternoon Market Update: U.S. Stocks Turn Higher; J.Jill Shares Plummet,2017-08-29 14:32:00-04:00,CTLT,positive
312838.0,12 Biggest Mid-Day Gainers For Tuesday,2017-08-29 12:21:00-04:00,CTLT,neutral
312839.0,Mid-Day Market Update: Movado Rises After Strong Q2 Results; Finish Line Shares Slide,2017-08-29 12:05:00-04:00,CTLT,positive
312840.0,"In Its Best Year Since Going Public, Q4 A Catalyst For Catalent",2017-08-29 11:44:00-04:00,CTLT,positive
312841.0,Mid-Morning Market Update: Markets Open Lower; Best Buy Tops Q2 Estimates,2017-08-29 10:13:00-04:00,CTLT,positive
312842.0,A Peek Into The Markets: U.S. Stock Futures Signal Lower Start On Wall Street,2017-08-29 07:11:00-04:00,CTLT,negative
312843.0,"7 Stocks To Watch For August 29, 2017",2017-08-29 05:16:00-04:00,CTLT,neutral
312844.0,"Catalent Sees FY18 Adj. Net Income $192M-$212M, Sales $2.16B-$2.24B vs $2.02B Est.",2017-08-28 16:17:00-04:00,CTLT,neutral
312845.0,"Catalent Reports Q4 Adj. EPS $0.65 vs $0.57 Est., Sales $616.9M vs $549.53M Est.",2017-08-28 16:16:00-04:00,CTLT,neutral
312846.0,"5 Stocks To Watch For August 28, 2017",2017-08-28 05:21:00-04:00,CTLT,neutral
312847.0,"Earnings Scheduled For August 28, 2017",2017-08-28 04:13:00-04:00,CTLT,neutral
312848.0,Catalent Sees FY17 Sales $1.94-$1.98B vs $1.96B Est.,2017-05-04 16:17:00-04:00,CTLT,neutral
312849.0,"Catalent Reports Q3 EPS $0.38 vs $0.37 Est., Sales $532.6M vs $472M Est.",2017-05-04 16:17:00-04:00,CTLT,neutral
312850.0,Catalent Sees FY17 Rev. $1.94-$1.98B vs. Est. $1.95B,2017-02-06 16:16:00-05:00,CTLT,neutral
312851.0,"Catalent Reports Q2 EPS $0.27 vs. Est. $0.27, Rev. $483.7M vs. Est. $472.5M",2017-02-06 16:16:00-05:00,CTLT,neutral
312852.0,"Earnings Scheduled For February 6, 2017",2017-02-06 04:36:00-05:00,CTLT,neutral
312853.0,"Goldman Sachs Initiates Coverage On Catalent at Neutral, Announces $25.00 Target",2016-12-01 05:28:00-05:00,CTLT,neutral
312854.0,"Catalent Acquires Accucaps to Expand Softgel Development and Manufacturing Capabilities and Capacity, Terms nOt Disclosed",2016-11-28 07:30:00-05:00,CTLT,positive
312855.0,Catalent Sees FY17 Rev. $1.92-$1.995B vs. Est. $1.95B,2016-11-07 16:25:00-05:00,CTLT,neutral
312856.0,"Catalent Reports Q1 EPS $0.16 vs. Est. $0.15, Rev. $442.2M vs. Est. $430.2M",2016-11-07 16:25:00-05:00,CTLT,neutral
312857.0,Benzinga's Top Initiations,2016-10-20 09:14:00-04:00,CTLT,positive
312858.0,"KeyBanc Initiates Coverage On Catalent, Inc. Common Stock at Overweight",2016-10-20 03:57:00-04:00,CTLT,negative
312859.0,"Stephens & Co. Initiates Coverage On Catalent, Inc. Common Stock at Overweight",2016-10-18 07:26:00-04:00,CTLT,negative
312860.0,Lock-Up Expiries Expected Today From Ollie's Bargain Outlet And Catelent Inc,2016-10-07 08:15:00-04:00,CTLT,positive
312861.0,"Catalent Reports Purchase of Pharmatek, No Terms Disclosed",2016-09-13 07:30:00-04:00,CTLT,negative
312862.0,15 Biggest Mid-Day Losers For Wednesday,2016-09-07 13:21:00-04:00,CTLT,negative
312863.0,22 Stocks Moving In Wednesday's Pre-Market Session,2016-09-07 08:28:00-04:00,CTLT,neutral
312864.0,Catalent Announces Secondary Offering Of 19M Shares Common Stock,2016-09-06 17:22:00-04:00,CTLT,positive
312865.0,10 Stocks You Should Be Watching Today,2016-08-30 05:08:00-04:00,CTLT,neutral
312866.0,Hershey And 6 Others Stocks Moving In Monday's After-Hours Session,2016-08-29 17:19:00-04:00,CTLT,neutral
312867.0,Catalent Sees FY17 Rev. $1.92-$1.995B vs. Est. $1.92B,2016-08-29 16:17:00-04:00,CTLT,neutral
312868.0,"Catalent Reports Q4 Adj. EPS $0.52 vs. Est. $0.53, Rev. $532.2M vs. Est. $502.2M",2016-08-29 16:16:00-04:00,CTLT,neutral
312869.0,"Must Watch Stocks for August 29, 2016",2016-08-29 05:01:00-04:00,CTLT,neutral
312870.0,"Earnings Scheduled For August 29, 2016",2016-08-29 04:03:00-04:00,CTLT,neutral
312871.0,Benzinga's Top Upgrades,2016-06-21 08:52:00-04:00,CTLT,positive
312872.0,Wells Fargo Upgrades Catalent to Outperform,2016-06-21 06:58:00-04:00,CTLT,positive
312873.0,Benzinga's Top Upgrades,2016-06-20 08:52:00-04:00,CTLT,positive
312874.0,"Catalent Files For Potential Mixed Shelf, no terms",2016-06-06 16:53:00-04:00,CTLT,negative
312875.0,5 Rumors That Surfaced During Wednesday Trade,2016-06-01 18:56:00-04:00,CTLT,neutral
312876.0,Option Alert: CTLT Jun16 25.0 Puts Sweep: 500 @  ASK  $0.90: 1541 traded vs 304 OI: $27.69 Ref,2016-06-01 14:29:00-04:00,CTLT,positive
312877.0,"Catalent Shares Volatile Over Last Few Mins, Down ~$0.40; Hearing Unconfirmed Chatter Lonza Takeover Could Be Off the Table",2016-06-01 13:43:00-04:00,CTLT,positive
312878.0,William Blair Downgrades Catalent to Market Perform,2016-05-05 06:46:00-04:00,CTLT,neutral
312879.0,Catalent Sees FY16 Adj. Net Income $145M-$160M,2016-05-04 16:22:00-04:00,CTLT,neutral
312880.0,"Catalent Reports Q3 Adj. EPS $0.20 vs $0.31 Est., Sales $438M vs $427M Est.",2016-05-04 16:22:00-04:00,CTLT,neutral
312881.0,"Morgan Stanley Downgrades Catalent to Ewu, Maintains $30.00 PT",2016-04-21 08:49:00-04:00,CTLT,neutral
312882.0,"Benzinga's M&A Chatter for Wednesday April 13, 2016",2016-04-13 20:39:00-04:00,CTLT,neutral
312883.0,"Shares of Catalent Halted on Circuit Breaker, Up 12.6%",2016-04-13 14:06:00-04:00,CTLT,positive
312884.0,Hearing Lonza Group Has Approached Catalent Related to Takeover Offer,2016-04-13 14:06:00-04:00,CTLT,neutral
312885.0,Catalent Spikes to High of  $28.46 on Volume,2016-04-07 10:11:00-04:00,CTLT,neutral
312886.0,"Catalent Reports Q2 EPS $0.24 vs. Est. $0.34, Rev. $454.9M vs. Est. $440M",2016-02-09 16:17:00-05:00,CTLT,neutral
312887.0,Stocks Hitting 52-Week Lows,2016-02-08 10:08:00-05:00,CTLT,negative
312888.0,Catalent Reports Research Collab Deal with Roche for SMARTag Technology,2016-01-13 07:02:00-05:00,CTLT,neutral
312889.0,The Top 20 Wall Street Analysts Of 2015,2015-12-17 10:44:00-05:00,CTLT,positive
312890.0,Raymond James Downgrades Catalent to Market Perform,2015-12-09 09:08:00-05:00,CTLT,neutral
312891.0,"Catalent Reports Q1 EPS $0.16 vs. Est. $0.21, Rev. $423M vs. Est. $405.65M",2015-11-03 16:17:00-05:00,CTLT,neutral
312892.0,Morning Market Losers,2015-09-03 09:52:00-04:00,CTLT,negative
312893.0,Catalent Sees FY16 Rev. $1.81-$1.91B vs. Est. $1.82B,2015-09-02 16:14:00-04:00,CTLT,neutral
312894.0,"Catalent Reports Q2 Adj EPS $0.61 Vs Est $0.58, Sales $510.1M vs Est $496.9M",2015-09-02 16:01:00-04:00,CTLT,neutral
312895.0,"Earnings Scheduled For September 2, 2015",2015-09-02 04:04:00-04:00,CTLT,neutral
312896.0,Catalent Prices 14M Share Offering by Selling Shareholders @$29.00/Share,2015-06-03 04:37:00-04:00,CTLT,positive
312897.0,US Stock Futures Slightly Higher Ahead Of Economic Data,2015-06-01 07:03:00-04:00,CTLT,neutral
312898.0,Catalent Announces 20M Share Secondary Public Offering of Common Stock,2015-06-01 06:31:00-04:00,CTLT,positive
312899.0,S-1 from Catalent Shows Registration for 20M Share Offering via Selling Shareholders,2015-05-22 16:43:00-04:00,CTLT,positive
312900.0,"Catalent Reports Q3 Adj. EPS $0.46 vs $0.43 Est., Sees FY15 Sales $1.8B-$1.83B vs $1.84B Est.",2015-05-05 16:30:00-04:00,CTLT,neutral
312901.0,Catalent Announces 20M Share Offering by Selling Shareholders,2015-03-02 07:11:00-05:00,CTLT,positive
312902.0,Catalent Says Selling Stockholders Offering 20M Shares of Common Stock; Catalent Says Won't Receive Any Proceeds From Sale,2015-02-20 06:52:00-05:00,CTLT,positive
312903.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,CTLT,neutral
312904.0,UPDATE: Bank Of America Reiterates On Catalent On Operationally Solid F1Q,2014-11-14 10:02:00-05:00,CTLT,positive
312905.0,"Bank of America Maintains Buy on Catalent, Raises PT to $28.00",2014-11-14 04:23:00-05:00,CTLT,neutral
312906.0,Catalent Buys Micron Technologies,2014-11-13 16:11:00-05:00,CTLT,neutral
312907.0,Catalent Reports Q1 EPS of $0.13 vs $0.20 Est; Revenue of $418.30M vs $411.15M Est,2014-11-13 16:08:00-05:00,CTLT,neutral
312908.0,Catalent Appoints Steven Fasman Senior VP and General Counsel,2014-10-14 09:06:00-04:00,CTLT,neutral
312909.0,"Catalent Expands Its Technology Offerings In Biologics, Acquires Redwood Bioscience Inc. And The SMARTagTechnology Platform",2014-10-02 09:05:00-04:00,CTLT,positive
312910.0,Stocks Hitting 52-Week Highs,2014-09-16 10:04:00-04:00,CTLT,neutral
312911.0,UPDATE: Morgan Stanley Initiates Coverage On Catalent Inc On Good Market Position,2014-09-09 10:50:00-04:00,CTLT,positive
312912.0,UPDATE: J.P. Morgan Initiates Coverage On Catalent Inc On Market Leader Position,2014-09-09 09:10:00-04:00,CTLT,neutral
312913.0,"Deutsche Bank Initiates Coverage on Catalent at Hold, Announces $25.00 PT",2014-09-09 08:38:00-04:00,CTLT,neutral
312914.0,"Jefferies Initiates Coverage on Catalent at Buy, Announces $26.50 PT",2014-09-09 08:37:00-04:00,CTLT,neutral
312915.0,"Raymond James Initiates Coverage on Catalent at Outperform, Announces $27.00 PT",2014-09-09 08:37:00-04:00,CTLT,neutral
312916.0,"Piper Jaffray Initiates Coverage on Catalent at Overweight, Announces $28.00 PT",2014-09-09 05:34:00-04:00,CTLT,negative
312917.0,"JP Morgan Initiates Coverage on Catalent at Overweight, Announces $28.00 PT",2014-09-09 05:34:00-04:00,CTLT,neutral
312918.0,Catalent Reaffirms Outlook,2014-09-08 16:30:00-04:00,CTLT,neutral
312919.0,Catalent Sees FY2015 Sales $1.89B-1.92B,2014-09-04 17:31:00-04:00,CTLT,neutral
312920.0,Stocks Hitting 52-Week Highs,2014-08-08 10:21:00-04:00,CTLT,neutral
312921.0,"IPO for Catalent Opens at $20/Share, Priced at $20.50",2014-07-31 09:42:00-04:00,CTLT,neutral
312922.0,Waiting on 11 IPOs This Morning,2014-07-31 09:34:00-04:00,CTLT,neutral
312923.0,IPO Lookout: Busy Week Brings The Biggest IPO Since Facebook,2014-07-28 15:50:00-04:00,CTLT,neutral
312924.0,Catalent Expects 42.5M Share IPO to Price $19.00-$22.00/Share,2014-07-18 06:40:00-04:00,CTLT,positive
